BioMarin Halts Voxzogo Phase 2 Trials in Turner Syndrome, SHOX Deficiency & ACAN Deficiency After SCFE Safety Events

BioMarin is discontinuing Phase 2 Voxzogo trials for Turner Syndrome, SHOX-deficiency and ACAN-deficiency after SCFE events in investigator-sponsored studies. Noonan syndrome and most ISS trials continue as planned.